Abstract
Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist with an enormous spectrum of indications across anesthesiology, critical care, emergency medicine, pain medicine, and psychiatry. Specific indications supported by the literature include acute surgical pain of moderate-to-severe intensity, especially in those patients who are opioid tolerant or with known obstructive sleep apnea; chronic pain, especially in the context of neuropathic states such as complex regional pain syndrome and spinal cord injury; mood disorders, especially treatment-resistant depression; and as adjunct therapy for opioid taper. Side effects are largely related to its activity as an indirect sympathomimetic, and include bronchodilation, tachycardia and hypertension, and hallucinations or vivid dreams, among others; at the subanesthetic doses relevant to this review, ketamine is generally well-tolerated. Although there is enormous variability in dosing strategies present in the literature, baseline recommendations for dosing and patient monitoring are presented within.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456–66.
Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43:521–46.
Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat. 2017;74(4):399–405.
Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Curr Opin Neurobiol. 2016;36:112–7.
Sleigh J, Harvey M, Voss L, et al. Ketamine – more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76–81.
Williams NR, Heifets BD, Blasey CB, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. Published online in advance of print. 175:1205–15. https://doi.org/10.1176/appi.ajp.2018.18020138.
Pacheco DF, Romero TRL, Duarte IDG. Central antinociception induced by ketamine is mediated by endogenous opioids and mu- and delta-opioid receptors. Brain Res. 2014;1562:69–75.
Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011;58:911–23.
Loftus RW, Yeager MP, Clark JA, et al. Intraoperative ketamine reduces perioperative opiate consumption in opiate-dependent patients with chronic back pain undergoing back surgery. Anesthesiology. 2010;113:639–46.
Assouline B, Tramer MR, Kreienbuhl L, et al. Benefit and harm of adding ketamine to an opioid in a patient-controlled analgesia device for the control of postoperative pain: systematic review and meta-analyses of randomized controlled trials with trial sequential analyses. Pain. 2016;157:2854–64.
Iacobucci GJ, Visnjevac O, Pourafkari L, et al. Ketamine: an update on cellular and subcellular mechanisms with implications for clinical practice. Pain Physician. 2017;20:E285–301.
Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15:942–9.
Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13:245–9.
Schwartzman RJ, Alexander GM, Grothusen JR, et al. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147:107–15.
Koffler SP, Hampstead BM, Irani F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. 2007;22:719–29.
Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. 2008;9(8):1173–201.
Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950–66.
McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45:693–704.
Freye E, Latasch L, Levy JV. S(+)-ketamine attenuates increase in electroencephalograph activity and amplitude height of sensory-evoked potentials during rapid opioid detoxification. Anesth Analg. 2006;102(5):1439–44.
Strickler EM, Schwenk ES, Cohen MJ, et al. Use of ketamine in a multimodal analgesia setting for rapid opioid tapering in a profoundly opioid-tolerant patient: a case report. A A Pract. 2018;10(7):179–81.
Quinlan J. The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: outcome at 6 months. Pain Med. 2012;13:1524–5.
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
Patanwala AE, Martin JR, Erstad BL. Ketamine for analgosedation in the intensive care unit: a systematic review. J Intensive Care Med. 2017;32(6):387–95.
Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357–67.
Schwenk ES, Goldberg SF, Patel RD, et al. Adverse drug effects and preoperative medication factors related to perioperative low-dose ketamine infusions. Reg Anesth Pain Med. 2016;41:482–7.
Wan LB, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247–52.
Jouguelet-Lacoste J, La Colla L, Schilling D, et al. The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med. 2015;16:383–403.
Shahani R, Streutker C, Dickson B, et al. Ketamine associated ulcerative cystitis: a new clinical entity. Urology. 2007;69:810–2.
Gottrup H, Bach FW, Juhl G, et al. Differential effect of ketamine and lidocaine on spontaneous and mechanical evoked pain in patients with nerve injury pain. Anesthesiology. 2006;104:527–36.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fischer, M., Abd-Elsayed, A. (2019). Ketamine Infusion Therapy. In: Abd-Elsayed, A. (eds) Infusion Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-17478-1_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-17478-1_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17477-4
Online ISBN: 978-3-030-17478-1
eBook Packages: MedicineMedicine (R0)